NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCTs041220021

Registered date:25/05/2022

Clinical Trial for Prevention of Cisplatin-Induced Renal Nephrotoxicity

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedCancer
Date of first enrollment25/05/2022
Target sample size21
Countries of recruitment
Study typeInterventional
Intervention(s)flopropione dosing

Outcome(s)

Primary OutcomeOccurrence of adverse events
Secondary OutcomeChanges in cisplatin-induced nephrotoxicity markers

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximumNot applicable
GenderBoth
Include criteria- Has provided written consent for participation - Age 20 or greater at the time of consent - Has never received cisplatin-containing chemotherapy - Scheduled for chemotherapy with cisplatin only or cisplatin plus other anticancer agents under hospitalization - Lung, head and neck, and other cancer patients scheduled for cisplatin regimens with doses of 80 mg/m2 or higher in patients with
Exclude criteria- Presence of renal dysfunction: eGFR<60 mL/min/1.73 m2 - Pregnant or possibly pregnant women - Lactating women - With a history of hypersensitivity to flopropione - Deemed ineligible for the study as determined by the principal investigator or a co-investigator

Related Information

Contact

Public contact
Name Takenao Koseki
Address 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi Aichi Japan 470-1192
Telephone +81-562-93-9407
E-mail tkoseki@fujita-hu.ac.jp
Affiliation Fujita Health University
Scientific contact
Name Masashi Kondo
Address 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi Aichi Japan 470-1192
Telephone +81-562-93-9409
E-mail mkond@fujita-hu.ac.jp
Affiliation Fujita Health University Hospital